Abstract
Aim The aim of this study was to estimate the prevalence and causes of vision impairment (VI) in the Norwest of Portugal.
Methods Information about people with VI was obtained from different sources in the Norwest of Portugal during a period spanning years 2014-2015. Log-linear models were applied to estimate the number of individuals missing from lists of cases obtained from Primary Care Centres, blind association (ACAPO) and from hospitals (the PCVIP-study). Log-linear models were used to estimate the crude prevalence and the category specific prevalence of VI. Causes of VI were obtained from the PCVIP-study.
Results Crude prevalence of VI was 1.97% (95%CI=1.56-2.54), and normalized prevalence was 1% (95%CI=0.78-1.27). The age-specific prevalence was 3.27% (95% CI,=2.36-4.90), older than 64 years, 0.64% (95%CI=0.49-0.88), aged 25-64 years, and 0.07% (95%CI=0.045-0.13), aged less than 25 years. Prevalence amongst females was 1.3x higher than amongst males. The five leading causes of VI were Diabetic Retinopathy, Cataract, Age-related Macular Degeneration, Glaucoma and Disorders of the Globe.
Conclusion The prevalence of VI in Portugal was within the expected range and in line with other European countries. A significant number of cases of VI might be due to preventable cases and, therefore, a reduction of the prevalence of VI in Portugal seems possible. Women and old people were more likely to have VI and, therefore, these groups require extra attention. Future studies are necessary to characterize temporal changes in prevalence of VI in Portugal.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by FCT (COMPETE/QREN) grant reference PTDC/DPT-EPI/0412/2012 in the context of the Prevalence and Costs of Visual Impairment in Portugal: a hospital-based study (PCVIP-study). PLR is funded by FCT (COMPETE/QREN) grant reference SFRH/BD/119420/2016. AFM if founded by the faculty of Health and Life Sciences at Linnaeus University.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was conducted in accordance with the tenets of the Declaration of Helsinki, approved by the local ethics committees of the participating hospitals and by the ethical committee for Life Sciences and Health of the University of Minho, Ref. SECVS-084/2013; data protection process numbers 9936/2013 and 9793/ 2017.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
pedro.limaramos{at}lnu.se, ruisantana{at}ensp.unl.pt, patricia.marques{at}lshtm.ac.uk, isousa{at}math.uminho.pt, arsousa{at}med.up.pt
Data Availability
Upon request from the corresponding author